Abstract 3608
Background
Based on results of the phase 2 BOLT study (NCT01327053), sonidegib 200 mg once daily (QD) was approved in the US for patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy and in Switzerland and Australia also for metastatic BCC (mBCC). Here we report the final 42-month results—the longest follow-up data available from a hedgehog inhibitor (HHI) clinical trial—for a preplanned prespecified subgroup analysis for the primary endpoint, the objective response rate (ORR), in patients receiving 200 mg.
Methods
BOLT was a double-blind phase 2 study where HHI treatment–naïve patients with laBCC not amenable to curative surgery/radiotherapy, or with metastatic BCC (mBCC) were randomized 1:2 to sonidegib 200 or 800 mg QD, respectively. The primary endpoint was ORR. Analyses were performed at 12, 30, and 42 months after the last patient was randomized.
Results
For prespecified groups at 42 months, the ORRs for 200 mg QD were consistent for laBCC aggressive (59.5%; n = 37) and laBCC nonaggressive (51.7%; n = 29) histologies; male (43.8%; n = 48) and female (54.8%; n = 31); patients aged <65 years (59.4%; n = 32) and those aged ≥65 years (40.4%; n = 47); white (49.3%; n = 71) and nonwhite patients (37.5%; n = 8); and for patients not receiving (51.8%; n = 56) and those receiving (39.1%; n = 23) gastric pH agents. Subgroup analyses by disease strata (laBCC [56.1%; n = 66] vs mBCC [7.7%; n = 13]) and Eastern Cooperative Oncology Group performance status (0 [60%; n = 50] vs ≥ 1 [29.6%; n = 27;]) for the primary ORR endpoint showed heterogeneous results like those reported at 30 months. The safety/tolerability profile was consistent across 42 months with no new AEs emerging.
Conclusions
These results confirmed the consistency of treatment effect for sonidegib 200 mg QD at 42 months across several preplanned subgroups, including age, disease histology, gender, race, and use of gastric pH agents.
Clinical trial identification
NCT01327053.
Legal entity responsible for the study
Sun Pharmaceuticals Ltd.
Funding
Sun Pharmaceuticals Ltd.
Editorial Acknowledgement
Leonard Lionnet, PhD, CMPP of Lev Medical Communications provided medical writing support for this abstract.
Disclosure
R. Dummer: Consultant: Novartis Pharmaceuticals, Sun Pharma.
Resources from the same session
2848 - The influence of the surgical approach in women diagnosed with breast neoplasia
Presenter: Rogerio de Araujo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1197 - Use of comparative proteomics to identify potential cisplatin resistance mechanisms in neuroblastoma
Presenter: Miguel Angel Merlos Rodrigo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4058 - Acquired resistance mechanism of Osimertinib targeting EGFR in human lung cancer
Presenter: Vincenza Ciaramella
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1494 - Interaction of Oncostatin M and its receptor OSMR promotes gastric cancer progression via STAT3/FAK/Src signaling
Presenter: Liping Su
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4504 - Role of Pioglitazone on gene/protein expression profile, bioenergetics and TGF_/SMAD signaling pathway in NSCLC
Presenter: Raimondo Di Liello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4305 - Somatostatin receptor 2 expression and clinical significance in pulmonary lymphoepithelioma-like carcinoma
Presenter: Shuting Han
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
900 - The Role of Neurotrophic Factors in Nerve-Cancer Crosstalk
Presenter: Anu Planken
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1533 - Glutathione S-transferase M subfamily in TMZ-resistant glioblastoma cells
Presenter: Shu Yu Cheng
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
982 - Combining 2D angiogenesis and 3D Osteosarcoma microtissues to improve vascularization
Presenter: Hassan Chaddad
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5225 - Survival analysis of sorafenib in hepatocellular carcinoma patients with microvascular invasion after hepatectomy
Presenter: Zeyu Zhang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract